NCT07349277 Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia
| NCT ID | NCT07349277 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ammar Jassim Abed |
| Condition | Preeclampsia |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-10-10 |
| Primary Completion | 2026-01-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2025-10-10 with a primary completion date of 2026-01-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
his study investigates the effectiveness of three specific biological markers (biomarkers) in the blood-the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)-to better diagnose and monitor preeclampsia. Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage that affects 2-8% of pregnancies worldwide
Eligibility Criteria
IInclusion Criteria: * Pregnant women between 20 and 36 weeks of gestation * Age between 18 and 45 years * Attending the antenatal clinic at the study site Exclusion Criteria: * Chronic hypertension * Renal disease * Diabetes mellitus * Multiple gestations * Autoimmune disorders
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07349277 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Preeclampsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07349277 currently recruiting?
Yes, NCT07349277 is actively recruiting participants. Contact the research team at ammar.jassim11@gmail.com for enrollment information.
Where is the NCT07349277 trial being conducted?
This trial is being conducted at Nasiriyah, Iraq.
Who is sponsoring the NCT07349277 clinical trial?
NCT07349277 is sponsored by Ammar Jassim Abed. The trial plans to enroll 120 participants.